Health Care · NASDAQ: IDXX
IDEXX: how the business works
IDEXX makes the blood, urine and rapid tests that vets use to find out what is wrong with a pet, and had revenue of $4.30 billion in FY2025.
By Hardik Bhandare · Checked against filings: . Editorial policy. Corrections
Follow IDEXX
Email me when IDEXX's page is updated after earnings.
We'll send a confirmation email first. See our privacy policy.
IDEXX Laboratories, Inc. · Westbrook, Maine · Founded 1983
Updated for Q3 FY2026 · checked
- Revenue, FY2025
- $4.30B
- Net income, FY2025
- $1.06B
- Revenue from vet clinics, FY2025
- 91.9%
- Employees, Dec 31, 2025
- About 11,000
- Incorporated
- 1983
The short version
IDEXX in 5 points
1 · What it sells
IDEXX sells in-clinic analyzers and their test supplies, rapid SNAP tests, reference lab testing, clinic software and water tests, with revenue of $4.30 billion in FY2025.
2 · Who pays it
In FY2025, vet clinics and hospitals paid 91.9% of IDEXX's revenue, water utilities and labs 4.7%, livestock, poultry and dairy customers 3.1% and human medical customers and licensees 0.4%; IDEXX discloses no single customer's share.
3 · What it keeps from $100
Of every $100 that came in during FY2025, IDEXX kept $24.6 as net income after $6.2 of income tax and $0.9 of interest; operating income, before interest and tax, was $1.36 billion.
4 · Where the operating profit comes from
The Companion Animal Group earned $1,265 million of FY2025 segment operating income, Water $93.3 million and Livestock, Poultry and Dairy $3.2 million.
5 · The one thing to watch
U.S. same-store clinical visits fell about 2% in 2025, while CAG Diagnostics recurring revenue grew 11% in Q3 FY2026.
Sources: From IDEXX's FY2025 10-K, the Q3 FY2026 10-Q and the Q4 FY2025 and Q3 FY2026 earnings releases · checked
01Where the money goes · FY2025
Where does $100 of IDEXX's money go?
IDEXX · FY2025
Receipt for every $100
| Making products and running labs | $38.2 |
|---|---|
| Sales and marketing | $14.9 |
| General and administrative | $9.4 |
| Research and development | $5.8 |
| Interest | $0.9 |
| Income tax | $6.2 |
| Kept as net income | $24.6 |
| Total | $100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly $100 because of rounding.
How this is worked out
Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (revenue of $4.30 billion plus $3.0 million of interest income): each line = line ÷ $4.31 billion × 100.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report earnings, explained in 5 points.
No tips. Unsubscribe anytime.
We'll send a confirmation email. See our privacy policy.
02The business in one line
What does IDEXX do?
Vet clinics pay IDEXX for tests, lab work and software. Making products and running labs takes the biggest share of the money, and $24.6 of every $100 was left as net income in FY2025.
- Vet clinics and hospitals paid 91.9% of IDEXX's $4.30 billion of FY2025 revenue; water and farm animal tests brought in most of the rest.
- Making products and running labs took $38.2 of every $100 that came in during FY2025, and sales and marketing took $14.9.
03Who pays it
Who pays IDEXX?
Veterinary clinics and hospitals
91.9%
of revenue
Pay for in-clinic tests, analyzers, lab testing, rapid tests and software (Companion Animal Group).
Water utilities and testing labs
4.7%
of revenue
Pay for drinking water and wastewater tests (Water segment).
Livestock, poultry and dairy producers and labs
3.1%
of revenue
Pay for animal disease and milk quality tests (LPD segment).
Human medical customers and licensees
0.4%
of revenue
Pay for human blood gas and electrolyte tests and for licensed technology (Other).
- Veterinary clinics and hospitals91.9%
- Water utilities and testing labs4.7%
- Livestock, poultry and dairy producers and labs3.1%
- Human medical customers and licensees0.4%
How spread out the customers are
IDEXX does not disclose any single customer share of revenue. Its FY2025 10-K says vet clinics are consolidating into corporate hospital groups and buying groups.
Sources (1)
04How it makes money
How does IDEXX make money?
Each analyzer placed in a clinic keeps selling tests for years.
IDEXX places analyzers in clinics, then earns from the test supplies, lab work and software those clinics keep buying. Recurring diagnostics revenue was $3.41 billion in FY2025, 79.2% of total revenue (Cityfort calculation from the FY2025 10-K). The installed base of Catalyst chemistry analyzers grew from 69,000 at the end of 2023 to 78,000 at the end of 2025.
Net income kept per $100 of revenue
$23.2$24.6
FY2021 to FY2025
- IDEXX places an analyzer, such as Catalyst or inVue Dx, in a vet clinic.
- The clinic tests pets during visits and buys the supplies each test uses.
- Results flow into IDEXX software and the VetConnect PLUS portal.
- Clinics also send harder cases to IDEXX reference labs.
- Repeat spending pays for research into new tests that run on the same machines.
↺ Step 5 feeds back into step 1.
05Business segments · FY2025
Which businesses make up IDEXX?
Companion Animal Group (CAG)
91.9%Tests, analyzers, lab services and software for vets who treat pets.
Revenue $4.0B ($3,953M) · Operating profit $1.3B ($1,265M)
Water
4.7%Tests that check drinking water and other water for bacteria.
Revenue $201M · Operating profit $93.3M
Livestock, Poultry and Dairy (LPD)
3.1%Disease tests for farm animals and milk quality tests.
Revenue $132M · Operating profit $3.2M
Other
0.4%Human blood gas and electrolyte tests, plus licensing income.
Revenue $17.5M · Operating profit −$1M
How the mix changed
- Companion Animal Group (CAG)
- Water
- Livestock, Poultry and Dairy (LPD)
- Other
Revenue by segment, FY2023 to FY2025.
US$
See the numbers
06The numbers · Consolidated · US$
How has IDEXX done?
Revenue
$4.3BFY2025
Revenue grew every year from FY2021 to FY2025, from $3.22 billion to $4.30 billion, and reached $1.21 billion in Q3 FY2026.
US$
See the numbers
Net income
$1.1BFY2025
Net income rose from $744.8 million in FY2021 to $1.06 billion in FY2025, after a dip to $679.1 million in FY2022.
US$
See the numbers
Net income for every $100 of revenue
$24.6FY2025
IDEXX kept $24.60 of net income per $100 of revenue in FY2025, up from $20.20 in FY2022.
Net margin: $ of net income per $100 of revenue
See the numbers
Free cash flow
$1.1BFY2025
Free cash flow reached $1.06 billion in FY2025, up from $394.1 million in FY2022, when operating cash flow fell to $543.0 million.
US$ · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). Net income is the share belonging to the company's owners.
Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares
Sources (16)
- Form 10-K for FY2021
- Form 10-K for FY2022
- Form 10-K for FY2023
- Form 10-K for FY2024
- Form 10-K for FY2025
- Form 10-Q for Q1 FY2024
- Form 10-Q for Q2 FY2024
- Form 10-Q for Q3 FY2024
- Q4 FY2024 earnings release (8-K Exhibit 99.1)
- Q4 FY2025 earnings release (8-K Exhibit 99.1)
- Form 10-Q for Q1 FY2025
- Form 10-Q for Q1 FY2026
- Form 10-Q for Q2 FY2025
- Form 10-Q for Q2 FY2026
- Form 10-Q for Q3 FY2025
- Form 10-Q for Q3 FY2026
07Who runs it
Who runs IDEXX, and did they deliver?
Michael G. (Mike) Erickson, PhD
President and Chief Executive Officer · since 2026
Took over on May 12, 2026. He previously ran the point-of-care diagnostics and telemedicine business.
Jonathan (Jay) Mazelsky
Executive Chair (planned) · since 2026
CEO from 2019 to May 12, 2026. Under the plan in the 2026 proxy statementThe yearly filing about shareholder votes, the board and executive pay. Learn more, he was to serve as Executive Chair until he retires in May 2027.
Andrew Emerson
Executive Vice President, Chief Financial Officer and Treasurer · since 2025
CFO since March 2025; joined IDEXX in 2015.
Lawrence D. Kingsley
Independent Lead Director · since 2026
Independent Board Chair from November 2019; the 2026 proxy statement named him Lead Director after the 2026 annual meeting.
What they said, and what happened
1 delivered · 2 too early to tell
Said on May 1, 2025
IDEXX said on May 1, 2025 that it expected FY2025 revenue of $4,095 million to $4,210 million.
DeliveredWhat happened
FY2025 revenue was $4,303.7 million, above the range; the company had raised the range in August and November 2025.
Said on Feb 2, 2026
IDEXX said on Feb 2, 2026 that it expected FY2026 EPS of $14.29 to $14.80.
Too early to tellWhat happened
On Nov 2, 2026 it raised the range to $14.96 to $15.16. Full-year results are not out yet.
Said on Feb 2, 2026
IDEXX said on Feb 2, 2026 that it expected an FY2026 operating margin of 32.0% to 32.5%.
Too early to tellWhat happened
On Nov 2, 2026 it lowered the range from 32.3% to 32.5% (given Aug 4, 2026) to 32.1% to 32.3%, including acquisition impacts from the CoVet purchase.
Sources (10)
- CEO transition announcement, 8-K Exhibit 99.1 filed Jan 13, 2026
- Q3 FY2026 earnings release (8-K Exhibit 99.1)
- 2026 proxy statement (DEF 14A)
- Form 10-Q for Q3 FY2026
- Q1 FY2025 earnings release (8-K Exhibit 99.1)
- Q4 FY2025 earnings release (8-K Exhibit 99.1)
- Form 10-K for FY2025
- Q2 FY2025 earnings release (8-K Exhibit 99.1)
- Q3 FY2025 earnings release (8-K Exhibit 99.1)
- Q2 FY2026 earnings release (8-K Exhibit 99.1)
08What could go wrong
What could go wrong for IDEXX?
- Competition
Rivals with deep pockets
Mars (Antech, Heska) and Zoetis compete in pet lab tests and in-clinic analyzers. The 10-K says some rivals have greater financial resources and expects competition to grow, including from AI.
Watch CAG Diagnostics recurring revenue growth each quarter.
- Demand
Fewer pet visits to vets
U.S. same-store clinical visits fell about 2% in 2025. The 10-K says economic weakness could lead pet owners to skip or delay vet visits.
Watch U.S. clinical visit trends in each earnings release.
- Concentration
Clinics joining large groups
The 10-K says U.S. vet clinics are consolidating under corporate owners and buying groups. It says decisions by these larger buyers could hurt IDEXX profits.
Watch Any loss or gain of a corporate hospital group contract.
- Concentration
One supplier for chemistry slides
Ortho-Clinical Diagnostics is the sole source of certain Catalyst chemistry slides. The 10-K says some sole-source products cannot be readily replaced.
Watch Changes to the Ortho supply agreements (amendments effective May 19, 2026 were filed with the Q2 FY2026 10-Q).
- Currency
Sales outside the U.S. and currency swings
About 36% of FY2025 revenue came from outside the U.S., including 81% of LPD revenue. Currency moves change reported results, and trade or political events can disrupt sales.
Watch The gap between reported and organic growth.
- Execution
New CEO and an AI purchase
Mike Erickson became CEO on May 12, 2026, and IDEXX bought CoVet for about $250 million in September 2026. IDEXX said its lowered FY2026 operating margin outlook includes the impact of acquisitions.
Watch Operating margin against the 32.1% to 32.3% FY2026 range.
- Technology
Cyberattacks and AI errors
The 10-K says IDEXX and some of its vendors have faced cyberattacks, none with a material impact to its knowledge. It also warns that AI built into its products could cause harm to its reputation or legal liability.
Watch Any cyber incident disclosed in an 8-K or 10-Q.
09Supporters vs. critics
What do supporters and critics point to?
What supporters point to
- Revenue grew every year from FY2021 to FY2025, from $3.22 billion to $4.30 billion.
- Recurring diagnostics revenue was $3.41 billion in FY2025, 79.2% of total revenue (Cityfort calculation from the FY2025 10-K).
- The base of Catalyst chemistry analyzers in clinics grew from 69,000 at the end of 2023 to 78,000 at the end of 2025.
- Net debt was $651.3 million at Sep 30, 2026, about 0.4 times FY2025 EBITDA of $1.51 billion (Cityfort calculation from the Q3 FY2026 10-Q and the FY2025 10-K).
What critics point to
- U.S. same-store clinical visits fell about 2% in 2025, and the company said its initial 2026 outlook assumed a similar decline.
- Vet clinics paid 91.9% of FY2025 revenue, and the 10-K says these clinics are consolidating under corporate owners and buying groups.
- Ortho-Clinical Diagnostics is the sole source of certain Catalyst chemistry slides; the 10-K says some sole-source products cannot be readily replaced.
- The FY2025 10-K names Mars and Zoetis among IDEXX's rivals and says some rivals have greater financial resources.
- Rapid assay revenue rose 1% in Q3 FY2026; the company said price increases offset lower testing volumes.
10What to watch next
What should you watch next at IDEXX?
Next event
Q4 FY2026 results
Date not announced yet.
Results against the FY2026 range
IDEXX said on Nov 2, 2026 that it expects FY2026 revenue of $4,741 million to $4,767 million and EPS of $14.96 to $15.16. FY2025 revenue was $4.30 billion and EPS was $13.08.
Pet visits against repeat testing
U.S. same-store clinical visits fell about 2% in 2025. CAG Diagnostics recurring revenue grew 11% in Q3 FY2026.
inVue Dx placements
IDEXX placed over 1,900 inVue Dx analyzers in Q3 FY2026, bringing the installed base to nearly 11,000.
Operating margin after the CoVet purchase
IDEXX bought CoVet for about $250 million in September 2026. On Nov 2, 2026 it lowered its FY2026 operating margin range from 32.3% to 32.5% (given Aug 4, 2026) to 32.1% to 32.3%, including acquisition impacts.
11Key dates
What are the key dates for IDEXX?
| Event | Date | Source |
|---|---|---|
| $75 million of 3.72% senior notes dueShown as current debt in the Q3 FY2026 10-Q. | Form 10-Q for Q3 FY2026 | |
| Jay Mazelsky retires as Executive ChairPlanned for May 2027, per the 2026 proxy statement. | Not yet stated | 2026 proxy statement (DEF 14A) |
| Term loan matures$250.0 million term loan under the credit agreement. | Form 10-K for FY2025 |
Learn: What is an 8-K? A company's news report, with a real Adobe filing
12Key facts
Key facts about IDEXX
- What does IDEXX Laboratories do?
- IDEXX Laboratories makes the blood, urine and rapid tests that vets use to diagnose pets. It also runs about 80 reference labs and sells clinic software, X-ray systems and water tests.
- How does IDEXX make money?
- IDEXX places analyzers in vet clinics and then sells the test supplies, lab testing and software those clinics keep buying. Recurring diagnostics revenue was $3.41 billion in FY2025, 79.2% of total revenue (Cityfort calculation from the FY2025 10-K).
- Who are IDEXX's customers?
- Veterinary clinics and hospitals paid 91.9% of IDEXX's FY2025 revenue, water utilities and testing labs 4.7%, and livestock, poultry and dairy customers 3.1%. IDEXX does not disclose any single customer's share of revenue.
- How big is IDEXX?
- IDEXX had revenue of $4.30 billion and net income of $1.06 billion in FY2025, the year ended Dec 31, 2025. It had about 11,000 employees in about 34 countries at Dec 31, 2025.
- Where does IDEXX sell?
- The United States brought in 64% of IDEXX's FY2025 revenue. Europe, the Middle East and Africa brought in 21.8%, Asia Pacific 8.3%, Canada 3.9%, and Latin America and the Caribbean 2.1%.
- Who owns IDEXX?
- The 2026 IDEXX proxy statement lists The Vanguard Group with 12.2% and BlackRock with 9.56% of the common stock. IDEXX's directors and executive officers together owned about 0.2% at Mar 8, 2026 (Cityfort calculation from the 2026 proxy statement).
- Who runs IDEXX?
- Mike Erickson became IDEXX's President and Chief Executive Officer on May 12, 2026, taking over from Jay Mazelsky. Andrew Emerson has been IDEXX's Chief Financial Officer since March 2025.
- Does IDEXX pay a dividend?
- No. IDEXX's FY2025 10-K says it has never declared or paid a cash dividend. IDEXX spent $1.22 billion buying back its own shares in FY2025.
Terms on this page
- Capital expenditures (capex)
- Debt-to-equity
- Earnings per share (EPS)
- EBITDA
- Free cash flow
- Net debt
- Net margin
- Revenue vs net income
- Stock buyback
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
13What it sells
13What it sells
What does IDEXX sell?
In-clinic analyzers and their test supplies (IDEXX VetLab)
Machines such as Catalyst (blood chemistry), ProCyte (blood counts), SediVue (urine) and inVue Dx (cell samples) run tests during the visit. Their consumables brought in $1.50 billion in FY2025, against $200.2 million from selling the machines.
Reference lab testing
Clinics send samples to about 80 IDEXX labs worldwide, with results the same or next day for most tests. Lab testing and consulting brought in $1.42 billion in FY2025.
Rapid tests (SNAP)
Single-use kits, such as SNAP 4Dx Plus, that a vet reads in minutes. They brought in $349.0 million in FY2025.
Clinic software and imaging
Practice management software (Cornerstone, ezyVet, Animana, IDEXX Neo), digital X-ray systems (ImageVue) and the VetConnect PLUS results portal. This line brought in $345.9 million in FY2025.
Water tests
Tests such as Colilert that water utilities and labs use to check for bacteria like E. coli. The Water segment brought in $201.1 million in FY2025.
Livestock, poultry and dairy tests
Disease tests for cattle, pigs and poultry, and milk quality tests. This segment brought in $131.8 million in FY2025.
Think of it like this
It works a little like a printer maker: IDEXX places the analyzer once, then sells the test supplies it uses up for years.
What it does
- Does: Sells diagnostic tests and lab services to veterinary clinics, with products sold in more than 175 countries
- Does: Runs about 80 reference labs of its own
- Does: Sells software that clinics use to run appointments, records and billing
- Does: Sells water-quality tests and farm animal disease tests
What it does not do
- Does not: Pay a dividend: the FY2025 10-K says it has never declared one and has no intention to at this time
- Does not: Sell mainly to pet owners: its customers are vets, labs and water utilities
- Does not: Make most of its money from human medicine: human point-of-care tests and licensing were $17.5 million, 0.4% of FY2025 revenue
Sources (1)
14How the money flows
14How the money flows · FY2025
How does money flow through IDEXX?
Money in
- Revenue$4.3B
- Interest income$3M
The company
IDEXX
$4.3B came in
Money out
- Cost of revenue (making products and running labs)$1.6B
- Sales and marketing$644M
- General and administrative$405M
- Research and development$251M
- Interest expense$38.9M
- Income tax$265M
- Net income$1.1B
- Vets, labs and water utilities paid IDEXX $4.30 billion of revenue in FY2025.
- Making products and running its labs cost $1.64 billion, leaving $2.66 billion of gross profit.
- Sales and marketing took $643.5 million, administration $404.8 million and research $251.2 million.
- That left $1.36 billion of operating income; interest cost $38.9 million and interest earned added $3.0 million.
- Income tax took $264.7 million, and $1.06 billion was left as net income.
Sources (1)
15What it needs to run
15What it needs to run
What does IDEXX need to run?
Chemistry slides from Ortho-Clinical Diagnostics
Ortho, part of QuidelOrtho, supplies the dry slides used in Catalyst chemistry analyzers. The 10-K names it as a sole or single source, under agreements set to run to December 2044.
About 11,000 employees
IDEXX had about 11,000 employees in about 34 countries at Dec 31, 2025, including lab staff and a direct sales force.
Research spending
It spent $251.2 million on research and development in FY2025, 5.8% of revenue, to add new tests and analyzers.
Biological materials and outside suppliers
Many rapid assay, water and farm tests use antibodies, cells and sera that are hard to make. Some instruments are made by third parties, and cloud software runs on outside providers.
Sources (1)
16Where it sells
16Where it sells · FY2025
Where does IDEXX sell?
- United States64%
- Europe, Middle East and Africa21.8%
- Asia Pacific8.3%
- Canada3.9%
- Latin America and Caribbean2.1%
Sources (1)
17Competitors and what protects it
17Competitors and what protects it
Who does IDEXX compete with?
Mars, Incorporated (Antech Diagnostics, Heska)
The 10-K names its Antech and Heska brands as rivals in pet lab testing and in-clinic tests in North America and abroad, and in imaging.
Zoetis Inc. (Abaxis)
NYSE: ZTS
The 10-K names Zoetis and its Abaxis unit as a rival in pet diagnostics in North America and some international markets.
Covetrus, Inc.
The 10-K calls Covetrus its largest software rival in North America and the U.K., selling clinic systems alongside its animal health distribution business.
Neogen Corporation
Named in the 10-K as a rival in livestock, poultry and water testing, along with Charm Sciences, BioChek and Thermo Fisher Scientific.
Fujifilm Holdings
Named in the 10-K as a rival in pet diagnostics in some international markets and in diagnostic imaging.
What protects the business
Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.
- Installed base of analyzers4 of 5
About 78,000 Catalyst, 56,000 premium hematology and 24,000 SediVue analyzers were placed at Dec 31, 2025, each using IDEXX supplies.
- Recurring revenue4 of 5
CAG Diagnostics recurring revenue was $3.41 billion in FY2025, 79.2% of total revenue (Cityfort calculation from the FY2025 10-K).
- Own lab network3 of 5
About 80 reference labs give same-day or next-day results for most tests in North America, Europe and Asia Pacific.
- Steady new tests3 of 5
Research spending was $251.2 million in FY2025. In 2025 IDEXX added a cancer test for dogs, a cell-sample test on inVue Dx and a cortisol test on Catalyst.
Weak spot
Fewer pet visits
U.S. same-store clinical visits fell about 2% in 2025, and the company said its initial 2026 outlook assumed a similar decline. Average diagnostics revenue per U.S. practice still rose about 6% in 2025.
18Where growth could come from
18Where growth could come from
Where could IDEXX's growth come from?
IDEXX said on Nov 2, 2026 that it expects FY2026 revenue of $4,741 million to $4,767 million: growth of 10.1% to 10.8% as reported and 9.3% to 10.0% organic. It also guided to an operating margin of 32.1% to 32.3% and EPS of $14.96 to $15.16. Its first FY2026 revenue range, given on Feb 2, 2026, was $4,632 million to $4,720 million.
Repeat diagnostics spending by vets
Working+11% in Q3 FY2026
CAG Diagnostics recurring revenue grew 11% as reported and organic in Q3 FY2026, with 10% in the U.S. and 13% reported in international regions.
Status: Working, on track against what the company said.
inVue Dx cell analyzer
WorkingNearly 11,000 placed
The inVue Dx analyzer launched in late 2024. IDEXX placed over 1,900 of them in Q3 FY2026, bringing the installed base to nearly 11,000.
Status: Working, on track against what the company said.
In-clinic test supplies
Working+14% in Q3 FY2026
IDEXX VetLab consumables revenue grew 14% as reported in Q3 FY2026, supported by 11% growth in the global premium analyzer base, the company said.
Status: Working, on track against what the company said.
Rapid SNAP tests
Mixed+1% in Q3 FY2026
Rapid assay revenue rose 1% in Q3 FY2026; the company said price increases offset lower testing volumes.
Status: Mixed, partly on track.
AI software (CoVet)
NewAbout $250 million deal
IDEXX bought CoVetAI, maker of AI software that listens during vet visits and helps with clinical workflow, on Sep 15, 2026. It said CoVet added about $5 million to its FY2026 revenue guidance.
Status: New, recently announced.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
19The company's own measures (non-GAAP)
19The company's own measures · Q3 FY2026 and first nine months of FY2026
What do IDEXX's own measures show?
Official (GAAP): Diluted EPS, Q3 FY2026
$4.01
Company's own measure: Comparable EPS, Q3 FY2026
$3.96
IDEXX removes currency changes from the year before, tax benefits from share-based pay and unusual items. On this basis EPS grew 22%, against 18% growth in GAAP EPS.
Official (GAAP): Reported revenue growth, Q3 FY2026
10.0%
Company's own measure: Organic revenue growth, Q3 FY2026
10%
Organic growth removes the effect of currency changes, certain acquisitions and divestitures. Both measures were 10% in Q3 FY2026.
Official (GAAP): Cash from operations, first nine months of FY2026
$1.1B
Company's own measure: Free cash flow, first nine months of FY2026
$978M
IDEXX defines free cash flowCash from operations minus spending on buildings and equipment. Learn more as cash from operations minus $85.6 million spent on property and equipment.
These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (GAAP) figure.
Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out
20Financial strength and debt
20Financial strength · Sep 30, 2026
How much debt does IDEXX have?
- Total debt$849M
- Cash and investments$198M
- Net debt (debt minus cash)$651M
- Net worth (shareholders' money)$1.9B
- Debt to equity
- 0.45×
- $ of debt for every $1 of shareholders' money
- Total debt of $848.9 million is $474.0 million drawn on the credit facility plus $374.9 million of senior notes; minus $197.5 million of cash, that leaves net debt of $651.3 million (Cityfort calculation from the Q3 FY2026 10-Q).
- The $1.25 billion unsecured credit facility, signed Nov 13, 2025, includes a $250.0 million term loan due Nov 12, 2028; $773.2 million was still available at Sep 30, 2026.
- The senior notes are private placements: $75 million at 3.72% due Feb 12, 2027, $100 million at 4.19% due 2029 and $200 million at 2.50% due 2030. IDEXX repaid another $75 million of 3.72% notes on Sep 4, 2026.
- The only financial covenant caps debt at 3.5 times adjusted EBITDA; the 10-Q says IDEXX was in compliance.
- Goodwill rose from $414.0 million at Dec 31, 2025 to $640.5 million at Sep 30, 2026, a period that included the CoVet purchase. Debt here leaves out lease liabilities.
21Who owns it
21Who owns it · ownership as of Mar 8, 2026
Who owns IDEXX?
- Officers and directors (as a group), shares
- 0.2%
Share classes
Holders of 5% or more
From the company's proxy statement (DEF 14A), later Schedule 13G filings and the share counts on its latest annual or quarterly report. Each holder row shows the date of its own filing.
Learn: How to read a proxy statement (DEF 14A): Nvidia's 2026 proxy · Form 4 insider filings: who files, the codes and the footnotes
22What it does with profit
22What it does with profit
What does IDEXX do with its profit?
Buyback · Dec 31, 2023
Bought back 155,000 shares on the open market for $72.6 million in FY2023.
$72.6M
Buyback · Dec 31, 2024
Bought back 1.74 million shares on the open market for $848.9 million in FY2024.
$849M
Buyback · Dec 31, 2025
Bought back 2.41 million shares on the open market for $1.22 billion in FY2025, at an average of $506.07 a share.
$1.2B
Buyback · Sep 30, 2026
Bought back 1.37 million shares on the open market for $804.7 million in the first nine months of FY2026.
$805M
Sources (2)
23Governance signals
23Governance signals
What do IDEXX's governance filings show?
- Auditor
- PricewaterhouseCoopers LLP, since 2002
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- The 2026 proxy statement says there were no related person transactions needing Audit Committee review since Jan 1, 2025. It lists 11 directors for the board after the 2026 annual meeting, and nine are independent. The two who are not are Erickson and Mazelsky.
- Credit rating
- Not checked for this page
24How it got here
24How it got here
How did IDEXX get here?
1983
Milestone
Incorporated in Delaware
IDEXX was incorporated in 1983; it is based in Westbrook, Maine.
2015
Business-model change
Started selling directly to vets
Since 2015 IDEXX has moved to marketing its pet diagnostics directly to vets and practice owners.
2019
Milestone
Jay Mazelsky became CEO
Lawrence Kingsley became independent Board Chair in November 2019.
2024
Milestone
inVue Dx launched
A new analyzer that reads cell samples in the clinic; nearly 11,000 were installed by Sep 30, 2026.
2025
Milestone
New $1.25 billion credit facility
Signed Nov 13, 2025; the earlier $250.0 million term loan was repaid in October 2025.
2026
Milestone
Mike Erickson became CEO
He took over from Jay Mazelsky on May 12, 2026; under the plan in the 2026 proxy statement, Mazelsky was to serve as Executive Chair until he retires in May 2027.
2026
Business-model change
Bought CoVet, an AI software maker
IDEXX paid about $250 million on Sep 15, 2026 for CoVetAI, whose AI software listens during vet visits and helps with clinical workflow.
25Sources and changes
Where every number on this page comes from
Sources (24 documents)
- S1Form 10-Q for Q3 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Nov 2, 2026
- S2Form 10-Q for Q2 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Aug 4, 2026
- S3Form 10-Q for Q1 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · May 5, 2026
- S4Form 10-K for FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Feb 20, 2026
- S5Form 10-Q for Q3 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Nov 3, 2025
- S6Form 10-Q for Q2 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Aug 4, 2025
- S7Form 10-Q for Q1 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · May 1, 2025
- S8Form 10-K for FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Feb 21, 2025
- S9Form 10-Q for Q3 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Oct 31, 2024
- S10Form 10-Q for Q2 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Aug 6, 2024
- S11Form 10-Q for Q1 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · May 1, 2024
- S12Form 10-K for FY2023 · SEC EDGAR · Tier 1: company or exchange filing · Feb 22, 2024
- S13Form 10-K for FY2022 · SEC EDGAR · Tier 1: company or exchange filing · Feb 16, 2023
- S14Form 10-K for FY2021 · SEC EDGAR · Tier 1: company or exchange filing · Feb 16, 2022
- S152026 proxy statement (DEF 14A) · SEC EDGAR · Tier 1: company or exchange filing · Mar 27, 2026
- S16Q3 FY2026 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Nov 2, 2026
- S17Q2 FY2026 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Aug 4, 2026
- S19Q4 FY2025 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 2, 2026
- S20Q3 FY2025 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Nov 3, 2025
- S21Q2 FY2025 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Aug 4, 2025
- S22Q1 FY2025 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · May 1, 2025
- S23Q4 FY2024 earnings release (8-K Exhibit 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 3, 2025
- S24Credit agreement, 8-K Exhibit 10.1 filed Nov 13, 2025 · SEC EDGAR · Tier 1: company or exchange filing · Nov 13, 2025
- S25CEO transition announcement, 8-K Exhibit 99.1 filed Jan 13, 2026 · SEC EDGAR · Tier 1: company or exchange filing · Jan 13, 2026
Changes to this page (v1 · Nov 20, 2026)
- v1 · Nov 20, 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.